Global Transient Ischemic Attack Market Research Report: Forecast to 2023


According to the WHO estimates, neurological disorders are responsible for 4.5 to 11% of all the disorders in the population including low or high-income economies.

SKU: 180349 Category: Tag:


Transient Ischemic Attack (TIA) is a neurological dysfunction which is caused by the loss of blood flow to the brain, spinal cord, or retina. The primary cause of the transient ischemic attack is a loss of blood supply to the brain which may occur due to various reasons, such as when blood vessels get blocked, blood supply to a part of the brain is lost, or a blood vessel leaks blood into the brain. However, the blockage can be caused by a blood clot that forms in the blood vessel (thrombosis), or it can be caused by a clot or debris that floats downstream.

The increasing prevalence of neurological disorders, increasing investments of biotechnology and pharmaceutical industries in R&D, and rising need for better treatment methods drive the growth of the market. Moreover, favorable reimbursement policies, increased application, and significant investments in the development of new technologies for the treatment of epilepsy and other cardiac indications are likely to fuel the market growth during the forecast period.

According to the WHO estimates, neurological disorders are responsible for 4.5 to 11% of all the disorders in the population including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

However, higher cost of this treatment procedure may hamper the market growth during the corresponding period. As per the American Heart Association, currently the treatment costs for
TIA is approximately USD 20,000 which includes the cost of only one year, and it is not affordable to the patients living in low-income economies.
The global transient ischemic attack market is expected to register a CAGR of 6.08% during the forecast period, 2017–2023.

Key Players
Some of key the players in the transient ischemic attack market are F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories, Novo Nordisk A S, Becton Dickinson and Company, Medtronic PLC, B. Braun Melsungen AG, Thermo Fisher Scientific Inc., Terumo Corporation, Ypsomed Holding AG, HTL-STREFA S.A., Sarstedt AG & Co, Owen Mumford Ltd., Greiner Bio-One, Improve Medical, Chengdu Rich Science Industry Co., Ltd., Weigao Group, Nipro, Medigard, Weihai Hongyu Medical Devices, and others.

Study Objectives
• To provide a detailed analysis of the market structure along with a forecast of the various segments and sub-segments of the global transient ischemic attack market
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
• To provide strategic profiling of key players in the market, and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global transient ischemic attack market
• To provide a detailed analysis of the value chain and supply chain of the global transient ischemic attack market

Target Audience
• Medical Device Companies
• Hospitals & Clinics
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities

Key Findings
• The global transient ischemic attack market is expected to reach USD 2,268.5 million by 2023 at a CAGR of 6.08%
• On the basis of diagnosis, the imaging technique segment market is expected to command the largest market share of 71.2% over the review period and is expected to grow at the fastest CAGR of 5.96% during the forecast period 2017–2023
• On the basis of treatment, the drugs segment is expected to command the largest market share of 59.2% over the review period, and the surgery segment is expected to grow at the fastest CAGR of 5.69% during the forecast period 2017–2023
• On the basis of age group, the 60+ years segment is expected to command the largest market share of 40.0% over the review period and 41-60 years is expected to register the fastest CAGR of 6.40% during the forecast period 2017–2023
• On the basis of end-user, the hospitals and clinics market is projected to reach USD 892.90 million by the end of 2023 at a CAGR of 6.31% from 2017 to 2023
• On the basis of region, the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. In 2016, the market was led by the Americas with 37.4% share.

The report also covers the regional analysis
• Americas
o North America
 U.S.
 Canada
o South America
• Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Republic of Korea
o Rest of Asia Pacific
• The Middle East & Africa
o United Arab Emirates
o Saudi Arabia
o Oman
o Kuwait
o Qatar
o Rest of the Middle East & Africa

Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of Study
3.3 List of Assumptions
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Increasing Preference for Minimally Invasive Procedures
5.2.2 Rising Prevalence of Chronic Disorders
5.2.3 Improvement in Reimbursement Scenario
5.2.4 Rising Geriatric Population
5.3 Restraints
5.3.1 Rising Treatment Cost and Hospital Stay
5.3.2 Lack of Skilled Physicians
5.4 Opportunities
5.4.1 New Advancements in Catheterization Devices
5.4.2 Guide Wire Assisted Surgery in Elderly Population
5.1 Mega Trends
5.1.1 Telemedicine
5.2 Macroeconomic Indicators
5.3 Technology Trends & Assessment

6 Market Factor Analysis
6.1 Porter’s Five Forces Model
6.1.1 Threat of New Entrants
6.1.2 Bargaining Power of Suppliers
6.1.3 Threat of Substitutes
6.1.4 Bargaining Power of Buyers
6.1.5 Intensity of Rivalry
6.2 Supply Chain Analysis
6.2.1 Research &Development
6.2.2 Manufacturing
6.2.3 Distribution
6.2.4 Marketing & Sales
6.2.5 Post-Sales Monitoring
6.3 Demand & Supply: Gap Analysis
6.4 Pricing Analysis
6.5 Investment Feasibility Analysis
7 Global Transient Ischemic Attack Market, by Diagnosis
7.1 Introduction
7.2 Imaging Techniques
7.2.1 Computed Tomography (CT) scan
7.2.2 Carotid Duplex Scanning
7.2.3 Magnetic Resonance Imaging
7.2.4 Echocardiography
8 Global Transient Ischemic Attack Market, by Treatment
8.1 Introduction
8.2 Surgery
8.3 Drugs
8.3.1 Surgery
8.3.2 Drugs Antithrombotic agents Antiplatelets Clopidogrel Aspirin Heparins ENOXAPARIN DALTEPARIN Fibrinolytics Tenecteplase Alteplase Antihypertensive agents Prazosin Moxonidine
9 Global Transient Ischemic Attack Market, by Age Groups
9.1 Introduction
9.2 0–18 years
9.3 19–40 years (Millennial)
9.4 41–60 years
9.5 60+ years
9.5.1 0-18 years
9.5.2 19-40 years
9.5.3 41-60 years
9.5.4 60+ years
10 Global Transient Ischemic Attack Market, by End-User
10.1 Introduction
10.2 Hospitals & Clinics
10.3 Diagnostic Centers
10.4 Research Laboratories
10.4.1 Hospitals
10.4.2 Diagnostic Centers
10.4.3 Research Laboratories
11 Global Transient Ischemic Attack Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America U.S. Canada
11.2.2 South America

11.3 Europe
11.3.1 Western Europe Germany France U.K. Italy Spain Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Asia Pacific
11.4.2 Japan
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Republic of Korea
11.4.7 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 Middle East and Africa
11.5.2 United Arab Emirates
11.5.3 Saudi Arabia
11.5.4 Rest of Middle East & Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
12.2 Company Share Analysis
12.3 Recent Developments, 2013–2018
13 Company Profiles
13.1 Koninklijke Philips N.V.
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Stryker Corporation
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Johnson & Johnson Services Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 Boston Scientific Corporation
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Sanofi
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Bayer AG
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Pfizer Inc.
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Siemens AG
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 F. Hoffmann-La Roche AG
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 GE Healthcare
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Penumbra, Inc.
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
13.12 Medtronic PLC
13.12.1 Company Overview
13.12.2 Financial Overview
13.12.3 Products Offering
13.12.4 Key Developments
13.12.5 SWOT Analysis
13.12.6 Key Strategy
13.13 Abbott Laboratories
13.13.1 Company Overview
13.13.2 Financial Overview
13.13.3 Products Offering
13.13.4 Key Developments
13.13.5 SWOT Analysis
13.13.6 Key Strategy
13.14 Merck & Co., Inc.
13.14.1 Company Overview
13.14.2 Financial Overview
13.14.3 Products Offering
13.14.4 Key Developments
13.14.5 SWOT Analysis
13.14.6 Key Strategy
13.15 Boehringer Ingelheim GmbH
13.15.1 Company Overview
13.15.2 Financial Overview
13.15.3 Products Offering
13.15.4 Key Developments
13.15.5 SWOT Analysis
13.15.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO’s Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
15.2 References

Additional information


Geography Covered

Date Published